目的 探究阿托伐他汀聯(lián)合坎地沙坦酯治療原發(fā)性高血壓的臨床療效。方法 選取2012年1月—2014年11月義馬煤業(yè)集團股份有限公司收治的原發(fā)性高血壓患者300例,隨機分為對照組和治療組,每組150例。對照組口服坎地沙坦酯片,2片/次,1次/d。治療組口服阿托伐他汀鈣片1片/次,1次/d,坎地沙坦酯片的用法用量同對照組。兩組患者均連續(xù)治療10周。觀察兩組的臨床療效,同時比較治療前后兩組患者收縮壓、舒張壓、超敏C反應(yīng)蛋白(hs-CPR)、內(nèi)皮素(ET)、一氧化氮(NO)的變化。結(jié)果 治療后,兩組總有效率分別為76.67%、90.67%,兩組比較差異有統(tǒng)計學(xué)意義(P <0.05)。治療后,兩組患者收縮壓、舒張壓、hs-CRP、ET均較治療前顯著降低,NO顯著升高,同組治療前后比較差異有統(tǒng)計學(xué)意義(P <0.05);且治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P <0.05)。結(jié)論 阿托伐他汀聯(lián)合坎地沙坦酯治療原發(fā)性高血壓具有較好的臨床療效,可改善患者的血管內(nèi)皮功能和炎癥反應(yīng),值得在臨床上進一步推廣和應(yīng)用。

Objective To explore the clinical effects of atorvastatin combined with candesartan cilexetil in treatment of primary hypertension. Methods Patients (300 cases) with primary hypertension in the General Hospital of Yima Mineral Co. Ltd. Group from January 2012 to November 2014 were randomly divided into control and treatment groups. Each group had 150 cases. Patients in control group were po administered with Candesartan Cilexetil Tablets, 2 tablets/time, once daily. Patients in treatment group were po administered with Atorvastatin Calcium Tablets, 1 tablet/time, once daily, and the usage and dosage of Candesartan Cilexetil Tablets were the same with the control group. Two groups were treated for 10 weeks. After treatment, the efficacy was evaluated, and the changes of systolic and diastolic blood pressure, hs-CPR, ET, and NO in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 76.67% and 90.67%, respectively, and there were differences between two groups (P < 0.05). After treatment, systolic and diastolic blood pressure, hs-CPR, and ET in two groups were significantly reduced, while NO in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Atorvastatin combined with candesartan cilexetil has clinical curative effect in treatment of primary hypertension, and can improve endothelial function and inflammatory response, which is worthy of further promotion and application in clinic.